Article Text

other Versions

Authors’ response: metformin and risk of hepatocellular carcinoma—a study focused on anti-diabetic agents
  1. Chun-Ying Wu1,
  2. Hsiao-Ping Chen2
  1. 1Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan
  2. 2Division of Gastroenterology, Taichung Veterans General Hospital, Taichung, Taiwan
  1. Correspondence to Professor Chun-Ying Wu, Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan, 155, Sec. 2, Linong Street, Taipei 112, Taiwan; chun{at}

Statistics from

We thank Singh et al1 for their letter commenting on our recent paper.2 The authors briefly summarised current evidence regarding the chemopreventive effects of statins on hepatocellular carcinoma (HCC) and noted the lack of analyses on the role of statins in HCC in our study.

We agree that the use of statins was found to be associated with a reduced risk of HCC according to previous studies.2 However, not only statins but also non-steroidal anti-inflammatory drugs (NSAIDs), aspirin, thiazolidinediones, antiviral agents, etc, were all reported to be associated with a lower …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles